Breaking News

Ori Biotech Delivers IRO Platform for CGT Manufacturing to Customers

Designed to increase throughput, decrease COGS, and reduce batch failures.

By: Kristin Brooks

Managing Editor, Contract Pharma

Oribiotech Ltd., a provider of cell and gene therapy (CGT) manufacturing technology, announces the first customer deliveries of the new IRO platform, specifically designed to help address the current challenges in CGT manufacturing. In December 2024, four IRO instruments were delivered to multiple contract development and manufacturing organizations (CDMOs) and a global pharmaceutical company.

Through its Lightspeed Early Access Program which generates data with partners, IRO has proven to automate better biology and address critical manufacturing bottlenecks to dramatically increase throughput, decrease COGS, and reduce batch failures, according to the company. By reducing labor requirements by up to 70%, reducing the cost of goods by up to 50%, cutting processing times by up to 25%, and accelerating tech transfer times from months to weeks, the IRO platform aims to advance therapy development timelines.

IRO has the flexibility needed for early R&D and the ability to scale into GMP manufacturing with the same instrument, consumables, and process for a seamless transition from R&D to GMP. By automating, digitizing, and standardizing the most time-consuming and labor-intensive parts of the cell and gene therapy manufacturing workflow, IRO aims to allow scientists to quickly optimize their processes.

“Research and development teams no longer have to sacrifice biological performance to gain the benefits of automation – IRO delivers both,” said Farlan Veraitch, PhD, CSO and Founder of Ori Biotech. “IRO offers the flexibility needed for R&D while maintaining the precision and control essential for GMP manufacturing. We’re excited that this technology is now in the hands of partners who will harness its potential to drive meaningful clinical impact for patients.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters